Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
778
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 433–444 of 778 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Recruiting Phase 4 Interventional

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

NCT07257484
Status at this site: Recruiting
View directory record Official record
Conditions
Obesity (Disorder), Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Interventions
Valemetostat Tosylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
Site status not listed — check the official record
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
Procedure · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting No phase listed Interventional

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

NCT00499330
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Cancer
Interventions
lobectomy, segmentectomy or wedge resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
373
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neonatal Neurological Observation With Video AI

NCT07628829
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Sedation, Sleep
Interventions
Continuous bedside video monitoring with AI anatomic landmark tracking for neurologic monitoring
Device
Lead sponsor
Artemis AI Labs
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Recruiting Phase 3 Interventional

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535
Status at this site: Recruiting
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 6:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions
ELI-002 7P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 6:16 AM EDT

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.